ProCE Banner Activity

Optimal Utilization of Ki67 Testing in HR-Positive/HER2-Negative Early Breast Cancer: Education and Resources for the Oncology and Pathology Healthcare Teams

Slideset Download
Download this slideset from a live workshop series to gain more insight into the optimal utilization of Ki67 testing in HR-positive/HER2-negative early breast cancer, including a review of the latest evidence and practical clinical insights from expert faculty.

Released: March 04, 2022

Expiration: March 03, 2023

Share

Faculty

Sara M. Tolaney

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by a partnership between the American Society for Clinical Pathology and Clinical Care Options, LLC.
ProCE Banner

Supporters

This activity is supported by an educational grant from

Lilly

Program Director Disclosure

Program Director

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Sara Tolaney, MD, has disclosed that she has received funds for research support (paid to her institution) from AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Exelixis, Genentech, Immunomedics/Gilead, Lilly, Merck, Nanostring, Nektar, Novartis, Odonate, Pfizer, Sanofi, and Seattle Genetics and consulting fees from 4D Pharma, AstraZeneca, Athenex, BeyondSpring, Bristol-Myers Squibb, Chugai, CytomX, Daiichi Sankyo, Eisai, Ellipses Pharma, Genentech, Immunomedics/Gilead, Infinity, Lilly, Mersana, Novartis, OncoPep, OncoSec, OncXerna, Pfizer, Puma, Sanofi, Samsung Bioepsis, Seattle Genetics, Zymeworks, and Zentalis.